University of Miami - Bascom Palmer Eye Institute
Welcome,         Profile    Billing    Logout  
 16 Trials 
35 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Price, Francis W
NCT05136443: Loteprednol Etabonate 0.25% for Prevention of Cornea Transplant Rejection

Completed
4
70
US
loteprednol etabonate 0.25% ophthalmic suspension, Eysuvis
Price Vision Group, Kala Pharmaceuticals, Inc.
Corneal Endothelial Dystrophy, Corneal Edema
09/23
09/23
PRECISE, NCT06428955: Evaluation of a Monofocal Intraocular Lens

Recruiting
4
44
US, RoW
CT LUCIA 621P
Carl Zeiss Meditec AG
Cataract
12/24
12/24
NCT05255107: Safety and Effectiveness of the PXL Platinum 330 System With Riboflavin Solution for Previously Untreated Corneal Ulcers

Recruiting
2/3
468
US
Standard of Care Therapy + CXL + Riboflavin 0.23% L Solution, Standard of Care Therapy + Sham CXL + Artificial Tears
Peschke GmbH
Keratitis, Corneal Ulcer
11/23
02/24
NCT05255016: Safety and Effectiveness of the PXL Platinum 330 System With Riboflavin Solution for Refractory Corneal Ulcers

Recruiting
2/3
488
US
PXL Platinum 330 system + Riboflavin 0.25% TE Solution, Sham CXL + Artificial Tears
Peschke GmbH
Keratitis, Corneal Ulcer
11/23
02/24
NCT04787471: Corneal Crosslinking for Treatment of Corneal Neovascularization

Recruiting
2/3
62
US
30 minute photoactivation of riboflavin 0.1%, 10 minute photoactivation of riboflavin 0.1%
Price Vision Group, Cornea Research Foundation of America
Corneal Neovascularization
07/25
09/25
NCT03922542: Comparison of Standard vs. Accelerated Corneal Crosslinking

Recruiting
2/3
510
US
riboflavin 0.1%, Riboflavin 0.1%
Price Vision Group
Keratoconus, Ectasia Corneal
06/26
07/26
ExCrossV, NCT06753916: Multi Site Trial for Vascularized High Risk Keratoplasty

Not yet recruiting
2
96
US
Corneal Donor Tissue with Cross Linking, Treatment, Corneal Donor Tissue without Cross Linking, Control
Massachusetts Eye and Ear Infirmary
Corneal Transplant Failure
01/28
01/31
Kay, Christine
NCT04671433 / 2020-002873-88: Gene Therapy Trial for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR Gene

Completed
3
97
Europe, Canada, US, RoW
Genetic: AAV5-hRKp.RPGR, botaretigene sparoparvovec
Janssen Research & Development, LLC, Janssen Research & Development, LLC
X-Linked Retinitis Pigmentosa
09/24
09/24
NAC Attack, NCT05537220: Oral N-acetylcysteine for Retinitis Pigmentosa

Recruiting
3
438
Europe, Canada, US, RoW
N-acetylcysteine, Placebo
Johns Hopkins University, National Eye Institute (NEI), Duke University, Emory University, Massachusetts Eye and Ear Infirmary, Mayo Clinic, Medical College of Wisconsin, Retina Foundation of the Southwest, Stanford University, University of California, Davis, University of Florida, University of Iowa, University of Miami, University of Michigan, University of Minnesota, University of Oklahoma, University of Southern California, University of Utah, University of Washington, University of Wisconsin, Madison, Vanderbilt University, Vitreo Retinal Associates, PA, University of Houston, Medical University of Graz, McGill University, Universität Tübingen, Centro Medico ABC, Radboud University Medical Center, University of Amsterdam, University Hospital, Basel, Switzerland, University College London Hospitals, Northwestern University, University of Pennsylvania
Retinitis Pigmentosa
12/28
12/28
MGT-RPGR-022, NCT04794101 / 2020-002255-37: Follow-up Gene Therapy Trial for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR Gene

Active, not recruiting
3
97
Europe, Canada, US, RoW
Genetic: AAV5-hRKp.RPGR Intermediate Dose, botaretigene sparoparvovec, Genetic: AAV5-hRKp.RPGR Low Dose
Janssen Research & Development, LLC, Janssen Research & Development, LLC
X-Linked Retinitis Pigmentosa
09/29
12/29
TEASE, NCT02402660: Phase 2 Tolerability and Effects of ALK-001 on Stargardt Disease

Recruiting
2
140
US
ALK-001, C20-D3-Retinyl Acetate, C20 Deuterated vitamin A, Placebo
Alkeus Pharmaceuticals, Inc.
Stargardt Disease, Stargardt Macular Degeneration, Stargardt Macular Dystrophy, Autosomal Recessive Stargardt Disease 1 (ABCA4-related)
12/24
03/25
PRISM, NCT05197270: 4D-150 in Patients with Neovascular (Wet) Age-Related Macular Degeneration

Recruiting
1/2
215
US
4D-150 IVT, Aflibercept IVT
4D Molecular Therapeutics
Neovascular (Wet) Age-Related Macular Degeneration
11/25
11/26
Galor, Anat
NCT06293300: Understanding and Treating Traumatic Brain Injury (TBI) Associated Photophobia With Botulinum Toxin Type A (BoNT-A)

Recruiting
2
50
US
BoNT A
University of Miami, United States Department of Defense
Traumatic Brain Injury
08/26
08/26
Rosa, Potyra
IIH EVOLVE, NCT05347147 / 2021-006664-24: A Trial to Determine the Efficacy and Safety of Presendin in IIH

Terminated
3
14
Europe, US, RoW
Presendin, Placebo
Invex Therapeutics Ltd., Premier Research Group plc, University Hospitals Birmingham Neuro Ophthalmology Reading Centre, Birmingham, UK, Iowa Visual Field Reading Centre, Iowa, USA
Idiopathic Intracranial Hypertension
09/23
10/23
NAC Attack, NCT05537220: Oral N-acetylcysteine for Retinitis Pigmentosa

Recruiting
3
438
Europe, Canada, US, RoW
N-acetylcysteine, Placebo
Johns Hopkins University, National Eye Institute (NEI), Duke University, Emory University, Massachusetts Eye and Ear Infirmary, Mayo Clinic, Medical College of Wisconsin, Retina Foundation of the Southwest, Stanford University, University of California, Davis, University of Florida, University of Iowa, University of Miami, University of Michigan, University of Minnesota, University of Oklahoma, University of Southern California, University of Utah, University of Washington, University of Wisconsin, Madison, Vanderbilt University, Vitreo Retinal Associates, PA, University of Houston, Medical University of Graz, McGill University, Universität Tübingen, Centro Medico ABC, Radboud University Medical Center, University of Amsterdam, University Hospital, Basel, Switzerland, University College London Hospitals, Northwestern University, University of Pennsylvania
Retinitis Pigmentosa
12/28
12/28
NCT05294978: EyeConic: Qualification for Cone-Optogenetics

Recruiting
N/A
1000
Europe, US, RoW
Optical coherence tomography (OCT)
University Hospital, Basel, Switzerland, Institute of Molecular and Clinical Ophthalmology Basel
Retinal Dystrophies
12/24
12/25
NCT05218928: Qualification for Cone-Optogenetics

Recruiting
N/A
1000
Europe, US, RoW
OCT
University Hospital, Basel, Switzerland, Institute of Molecular and Clinical Ophthalmology Basel, Switzerland
Retinal Dystrophies
04/22
12/22
Amescua, Guillermo
PUTT, NCT06213649: Parasitic Ulcer Treatment Trial

Recruiting
3
232
Europe, US, RoW
Polyhexamethylene biguanide (PHMB), Polyhexanide, Topical corticosteroid, Topical placebo
Jeremy Keenan, MD, MPH, Johns Hopkins University, Oregon Health and Science University, University of Illinois at Chicago, University of Michigan, University of California, Los Angeles, University of Pittsburgh, University of Pennsylvania, Columbia University, University of Iowa, University of Florida, Aravind Eye Care System, Moorfields Eye Hospital NHS Foundation Trust, Federal University of São Paulo, National Eye Institute (NEI)
Acanthamoeba Keratitis
07/28
07/28
SCUT II, NCT04097730: Steroids and Cross-linking for Ulcer Treatment

Completed
3
280
US, RoW
Moxifloxacin Ophthalmic, Difluprednate Ophthalmic, Riboflavin Ophthalmic, Corneal Cross-Linking with Riboflavin Ophthalmic, Topical Placebo
Thomas M. Lietman, Aravind Eye Care System, National Eye Institute (NEI), University of Miami, Stanford University
Keratitis Bacterial
05/24
09/24
ExCrossV, NCT06753916: Multi Site Trial for Vascularized High Risk Keratoplasty

Not yet recruiting
2
96
US
Corneal Donor Tissue with Cross Linking, Treatment, Corneal Donor Tissue without Cross Linking, Control
Massachusetts Eye and Ear Infirmary
Corneal Transplant Failure
01/28
01/31
Lam, Byron
IIH EVOLVE, NCT05347147 / 2021-006664-24: A Trial to Determine the Efficacy and Safety of Presendin in IIH

Terminated
3
14
Europe, US, RoW
Presendin, Placebo
Invex Therapeutics Ltd., Premier Research Group plc, University Hospitals Birmingham Neuro Ophthalmology Reading Centre, Birmingham, UK, Iowa Visual Field Reading Centre, Iowa, USA
Idiopathic Intracranial Hypertension
09/23
10/23
liMeliGhT, NCT06388200: A Phase 3 Study Of OCU400 Gene Therapy for the Treatment Of Retinitis Pigmentosa

Recruiting
3
150
US
Sub-Retinal Administration of OCU400-301
Ocugen
Retinitis Pigmentosa
06/25
10/26
NAC Attack, NCT05537220: Oral N-acetylcysteine for Retinitis Pigmentosa

Recruiting
3
438
Europe, Canada, US, RoW
N-acetylcysteine, Placebo
Johns Hopkins University, National Eye Institute (NEI), Duke University, Emory University, Massachusetts Eye and Ear Infirmary, Mayo Clinic, Medical College of Wisconsin, Retina Foundation of the Southwest, Stanford University, University of California, Davis, University of Florida, University of Iowa, University of Miami, University of Michigan, University of Minnesota, University of Oklahoma, University of Southern California, University of Utah, University of Washington, University of Wisconsin, Madison, Vanderbilt University, Vitreo Retinal Associates, PA, University of Houston, Medical University of Graz, McGill University, Universität Tübingen, Centro Medico ABC, Radboud University Medical Center, University of Amsterdam, University Hospital, Basel, Switzerland, University College London Hospitals, Northwestern University, University of Pennsylvania
Retinitis Pigmentosa
12/28
12/28
TEASE, NCT02402660: Phase 2 Tolerability and Effects of ALK-001 on Stargardt Disease

Recruiting
2
140
US
ALK-001, C20-D3-Retinyl Acetate, C20 Deuterated vitamin A, Placebo
Alkeus Pharmaceuticals, Inc.
Stargardt Disease, Stargardt Macular Degeneration, Stargardt Macular Dystrophy, Autosomal Recessive Stargardt Disease 1 (ABCA4-related)
12/24
03/25
PRODYGY, NCT05748873: Promising ROd-cone DYstrophy Gene TherapY

Recruiting
1/2
33
Europe, US
SPVN06
SparingVision
Retinitis Pigmentosa
03/25
03/29
LIGHTHOUSE, NCT05878860: ATSN-201 Gene Therapy in RS1-Associated X-linked Retinoschisis

Recruiting
1/2
21
US
ATSN-201
Atsena Therapeutics Inc.
X-linked Retinoschisis
10/25
10/29
NCT02161380: Safety Study of an Adeno-associated Virus Vector for Gene Therapy of Leber's Hereditary Optic Neuropathy

Active, not recruiting
1
28
US
injection of scAAV2-P1ND4v2 1.18x10e9 vg (Low),, AAV-ND4, injection of scAAV2-P1ND4v2 5.81 X10e9 vg (Med), injection of scAAV2-P1ND4v2 2.4 X10e10vg (High), injection of scAAV2-P1ND4v2 1.0 X10e11vg (Higher)
Byron Lam, National Eye Institute (NEI)
Leber's Hereditary Optic Neuropathy
03/23
03/25
Platypus, NCT05902962: SAD of IVT VP-001 in PRPF31 Mutation-Associated Retinal Dystrophy Subjects

Recruiting
1
20
US
VP-001
PYC Therapeutics
Retinal Dystrophy, PRPF31 Mutationassociated Retinal Dystrophy, RP11
05/24
05/24
NCT05294978: EyeConic: Qualification for Cone-Optogenetics

Recruiting
N/A
1000
Europe, US, RoW
Optical coherence tomography (OCT)
University Hospital, Basel, Switzerland, Institute of Molecular and Clinical Ophthalmology Basel
Retinal Dystrophies
12/24
12/25
NCT06140329: Natural History of Autosomal Dominant Optic Atrophy (ADOA), Caused by OPA1 Mutation

Recruiting
N/A
40
Europe, US, RoW
PYC Therapeutics
Autosomal Dominant Optic Atrophy, Optic Atrophy, Autosomal Dominant, Optic Atrophies, Hereditary, Kjer Optic Atrophy
03/26
06/26
POLARIS, NCT06435000: An Observational Study in Subjects to Follow the Progression of Stargardt Disease Type 1 (STGD1) Caused by Bi-Allelic Autosomal Recessive Mutations in the ABCA4 Gene

Recruiting
N/A
75
Europe, US
Splice Bio
Stargardt, Stargardt's Disease, Stargardt Disease, STGD1
12/26
02/27
PRIMA-FS-US, NCT03392324: PRIMA US-Feasibility Study in Atrophic Dry AMD

Active, not recruiting
N/A
5
US
PRIMA
Science Corporation, Pixium Vision LLC acts as sponosor in the US on behalf of Pixium Vision SA
Dry Age-related Macular Degeneration
12/25
12/25
Uni-Rare, NCT05589714: Universal Rare Gene Study: A Registry and Natural History Study of Retinal Dystrophies Associated With Rare Disease-Causing Genetic Variants

Recruiting
N/A
1500
Europe, Canada, US, RoW
Jaeb Center for Health Research, Foundation Fighting Blindness
Inherited Retinal Degeneration, Retinitis Pigmentosa
12/28
12/28
NCT05218928: Qualification for Cone-Optogenetics

Recruiting
N/A
1000
Europe, US, RoW
OCT
University Hospital, Basel, Switzerland, Institute of Molecular and Clinical Ophthalmology Basel, Switzerland
Retinal Dystrophies
04/22
12/22
Caldwell, Doris Ann
KEYNOTE-E02, NCT03485209 / 2017-005076-26: Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors

Active, not recruiting
2
352
Europe, Canada, US
tisotumab vedotin, TIVDAK, pembrolizumab, KEYTRUDA®, carboplatin, cisplatin
Seagen Inc., Genmab, Merck Sharp & Dohme LLC
Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Exocrine Pancreatic Cancer, Carcinoma, Squamous Cell of Head and Neck
02/26
11/26

Download Options